For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Japan’s 1st Western Herbal Medicine Antistax to Hit Shelves in June: SSP
May 24, 2013
- Vital KSK HD Reports Single-Product, Single-Price Agreements Reached with Nearly 100% of Customers by End of March
May 24, 2013
- Pfizer Discontinues PIII Study of Inotuzumab Ozogamicin for NHL
May 24, 2013
- About 80% of Drug Makers Have Introduced Web Seminars; Cost-savings, Increased Sales Reported
May 24, 2013
- Maker FTC’s Provisional GL Prohibits Offering of Refreshments, Bentos at Web Seminars When There is Only 1 Participant from a Single Medical Institution
May 24, 2013
- Zeria Will Launch FD Treatment in June, Finding Patients Key, President Ibe Says
May 23, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
May 23, 2013
- Meiji Seika Pharma’s Generic Sales Seen Reaching 30 Billion Yen a Year Ahead of Schedule
May 23, 2013
- Once-Monthly Injectable Abilify Reduces Total Psychiatric Hospitalization Rates following Disease Relapse: Otsuka, Lundbeck
May 23, 2013
- Efficacy of Major Depressive Disorder Treatment Vortioxetine Shown in Three of Four PIII Studies: Takeda and Lundbeck
May 23, 2013
- AZ Oncology Division to Provide Information Based on Patients’ Lifestyle
May 22, 2013
- Apo Plus Station Eyes Sales Force of 300 for Established Products
May 22, 2013
- Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
- GSK Shares Clinical Trial Data with Researchers before Statistical Analysis
May 22, 2013
- Major Dispensing Pharmacy Chain Operators Expect Record High Sales and Profits in FY2013
May 21, 2013
- Five Major Dispensing Pharmacy Chain Operators’ Profits Down Due to NHI Price Revision
May 21, 2013
- Allegra AGs Pitched as Affordable Original Drugs with Production by Sanofi
May 21, 2013
- ALS Treatment Ozanezumab Designated as Orphan Drug: GSK
May 21, 2013
- AZ, BMKK Launch Once-Weekly GLP-1 Receptor Agonist Bydureon
May 20, 2013
- Takeda Slips to 3rd Place in 25 Major Pharmas’ Operating Profit Ranking
May 20, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…